BioAtla
cab phase dose titration ongoing | BioAtla
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
21 of 55
Related slides by other companies
Nuvalent
Investor Presentation
February 2024
the path to patient impact program status first approved a toe pivotal data naive and study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in for her | Nuvalent
Nuvalent
Investor Presentation
April 2024
lated cone program status pivotal data naive and first approved product study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in i he | Nuvalent
Compass Therapeutics
Investor Presentation
January 2023
phase combination study patient demographics | Compass Therapeutics
Exscientia
Investor Presentation
October 2023
elucidate phase ongoing in advanced solid | Exscientia
Other recent decks by BioAtla
See all presentations (8 decks)
Investor Presentation
August 2023
Investor Presentation
May 2023
Investor Presentation
November 2022
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights